Live
Clinical OMICsReporter’s Notebook: Are One-Shot Gene Editors Ready to Tackle Chronic Illness?Thermo FisherIndustry Roundup: Thermo Fisher Scales Orbitrap Platform Across Research, Biopharma, and Environmental Testing at ASMS 2026 - Chromatography OnlineFierceBiotechASCO: Telix tees up pivotal test for Pluvicto challenger while eyeing ‘white space’ on radiopharma canvasAgilentAgilent Technologies 2Q 2026: Revenue $1.84B, EPS $1.2— 10-Q Summary - TradingViewFierceBiotechAt ASCO 2026, a ‘paradigm shift’ for a rare gut cancer loomsBioPharma DiveRallyBio tries again for reverse merger, this time with AvenzoEndpoints NewsThe cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that wayEndpoints NewsEpigenetic editing shows promise against chronic hep B infectionsFierceBiotechASCO, Ryght AI team up for breast cancer trial site selectionClinical OMICsSMArT Platform Improves Safety and Efficiency of CRISPR Editing in HSPCsClinical OMICsPancreatic Cancer Drug Doubles Survival While Reducing Side EffectsEndpoints NewsShionogi wins US approval for first pill to prevent Covid following exposure

Archive

Latest Oldest Clear
@Cygnus Biosciences (Beijing)Co.,Ltd
Total 1
Source Cygnus Biosciences (Beijing)Co.,Ltd
Query --